France cancels order for Merck's Covid-19 antiviral drug

accreditation
0:00
play article
Subscribers can listen to this article
Molnupiravir, the antiviral COVID-19 pill from Merck and Ridgeback Biotherapeutics.
Molnupiravir, the antiviral COVID-19 pill from Merck and Ridgeback Biotherapeutics.
Merck
  • France is the first country to publicly say it has cancelled an order for the Merck treatment.
  • The company released results in November showing the drug molnupiravir was less effective than previously thought. 
  • France has instead bought Pfizer's competing antiviral drug, Paxlovid.


France has cancelled its order for Merck & Co's Covid-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday.

France is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November suggesting its drug was markedly less effective than previously thought, reducing hospitalisations and deaths in its clinical trial of high-risk people by about 30%.

"The latest studies weren't good," Olivier Veran told BFM TV.

Merck did not immediately respond to Reuters' request for comment.

While vaccines are the primary weapons against Covid-19 for governments, there are hopes Merck and Pfizer's experimental pills could be a game-changer in reducing the chances of dying or hospitalisation for those most at risk of severe illness.

France had placed an early order for 50 000 doses of the drug molnupiravir developed by Merck and Ridgeback Biotherapeutics.

READ | Injection or pill? Phase 1 of oral Covid-19 vaccine study kicks off in South Africa

The cancellation would not incur a cost, Veran said.

In Italy, the special commissioner's office for the Covid-19 emergency said on November 18 it had received a mandate from the health ministry to buy 50 000 courses of Merck's pill and another 50 000 of Pfizer's one. "The contract has not yet been finalised but is in progress," a spokesperson for the commissioner told Reuters on Tuesday.

Italian drug regulator Aifa's head Nicola Magrini told a Senate committee on December 9 the two treatments could be available in Italy from the end of January.

However, regardless of the availability of the drugs, there will be assessments of their use, two top government scientific advisers told Reuters.

"There must and will be an evaluation, independently of the assessments of regulatory bodies," Walter Ricciardi, top adviser of health minister Roberto Speranza, told Reuters.

On Wednesday, Germany has already bought Merck's antiviral treatment, health minister Karl Lauterbach told Reuters.

"This is a binding order," he said, adding Berlin was also in talks with Pfizer about buying its antiviral drug.

READ | Pfizer says its oral Covid-19 pill can help prevent severe infection from the Omicron variant

The European Medicines Agency is expected to decide whether to approve the Merck and Pfizer pills in the new year.

Pfizer's Paxlovid has shown near 90% efficacy in preventing Covid-19 hospitalisations and deaths in high-risk patients.

France had purchased that drug instead, Veran said, without saying how many doses it had secured.

"France is lined up to get it before the end of January," Veran continued. The minister said it has not yet been decided whether the drug would be available over the counter in pharmacies.


If you come across Covid-19 vaccination information that you do not trust, read Covid-19 vaccine myths debunked: Get the facts here. If you can't find the facts you're looking for, email us at the address mentioned in the article and we will verify the information with medical professionals.

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Rand - Dollar
15.67
-0.1%
Rand - Pound
19.64
-0.1%
Rand - Euro
16.79
+0.1%
Rand - Aus dollar
11.15
-0.2%
Rand - Yen
0.12
+0.1%
Gold
1,862.31
-0.2%
Silver
22.06
-0.3%
Palladium
2,010.50
+0.1%
Platinum
957.50
+0.1%
Brent Crude
113.56
+0.1%
Top 40
61,177
0.0%
All Share
67,691
0.0%
Resource 10
74,345
0.0%
Industrial 25
71,771
0.0%
Financial 15
15,802
0.0%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE